CAVERJECT Drug Patent Profile
✉ Email this page to a colleague
When do Caverject patents expire, and when can generic versions of Caverject launch?
Caverject is a drug marketed by Pfizer and is included in three NDAs.
The generic ingredient in CAVERJECT is alprostadil. There are seven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the alprostadil profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Caverject
A generic version of CAVERJECT was approved as alprostadil by HIKMA on January 20th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAVERJECT?
- What are the global sales for CAVERJECT?
- What is Average Wholesale Price for CAVERJECT?
Summary for CAVERJECT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 3 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 105 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,231 |
| Drug Prices: | Drug price information for CAVERJECT |
| What excipients (inactive ingredients) are in CAVERJECT? | CAVERJECT excipients list |
| DailyMed Link: | CAVERJECT at DailyMed |
Recent Clinical Trials for CAVERJECT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| City of Hope Medical Center | Phase 3 |
Pharmacology for CAVERJECT
| Drug Class | Prostaglandin Analog Prostaglandin E1 Agonist |
| Mechanism of Action | Prostaglandin Receptor Agonists |
| Physiological Effect | Genitourinary Arterial Vasodilation Venous Vasodilation |
US Patents and Regulatory Information for CAVERJECT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-003 | Jun 27, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-004 | May 19, 1997 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020755-002 | Oct 1, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CAVERJECT IMPULSE | alprostadil | INJECTABLE;INJECTION | 021212-001 | Jun 11, 2002 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020755-001 | Oct 31, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-001 | Jul 6, 1995 | AP | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAVERJECT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-003 | Jun 27, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-002 | Jul 6, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-002 | Jul 6, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-004 | May 19, 1997 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-001 | Jul 6, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| Pfizer | CAVERJECT | alprostadil | INJECTABLE;INJECTION | 020379-001 | Jul 6, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAVERJECT
See the table below for patents covering CAVERJECT around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 0725642 | PROSTAGLANDINE E 1 STABILISEE (STABILIZED PROSTAGLANDIN E 1) | ⤷ Sign Up |
| Germany | 69421936 | ⤷ Sign Up | |
| Denmark | 0725642 | ⤷ Sign Up | |
| Australia | 688792 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 9511683 | ⤷ Sign Up | |
| Australia | 7716794 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
